Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akcea Therapeutics Inc (AKCA)

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,601,012
  • Shares Outstanding, K 93,901
  • Annual Sales, $ 64,870 K
  • Annual Income, $ -225,820 K
  • 60-Month Beta 1.44
  • Price/Sales 7.04
  • Price/Cash Flow N/A
  • Price/Book 5.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 2.10
  • Number of Estimates 2
  • High Estimate 2.26
  • Low Estimate 1.94
  • Prior Year -0.79
  • Growth Rate Est. (year over year) +365.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.15 +5.57%
on 01/06/20
19.87 -14.19%
on 12/26/19
-2.57 (-13.08%)
since 12/17/19
3-Month
16.15 +5.57%
on 01/06/20
21.70 -21.45%
on 12/16/19
-1.88 (-9.93%)
since 10/17/19
52-Week
13.90 +22.66%
on 10/02/19
35.82 -52.40%
on 02/28/19
-13.22 (-43.67%)
since 01/17/19

Most Recent Stories

More News
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform...

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
Akcea Retains Rights to AKCEA-APOCIII-LRx

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that, following a strategic portfolio...

NVS : 95.93 (+0.87%)
AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
Akcea Therapeutics Announces New Appointments to its Board of Directors

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall, J.D., as chair of the Akcea Board of Directors and...

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
Akcea Announces Appointment of New Chief Operating Officer

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating officer. In this role, Mr....

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase...

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing...

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
PFE : 40.51 (-0.25%)
Akcea Therapeutics to Present at Upcoming Investor Conferences

Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today...

AKCA : 17.05 (-4.11%)
IONS : 60.13 (-2.16%)
Akcea Therapeutics (AKCA) Reports Q3 Loss, Tops Revenue Estimates

Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 38.18% and 39.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AKCA : 17.05 (-4.11%)
Akcea Therapeutics: 3Q Earnings Snapshot

BOSTON (AP) _ Akcea Therapeutics Inc. (AKCA) on Tuesday reported a loss of $31.5 million in its third quarter.

AKCA : 17.05 (-4.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 18.06
1st Resistance Point 17.55
Last Price 17.05
1st Support Level 16.77
2nd Support Level 16.50

See More

52-Week High 35.82
Fibonacci 61.8% 27.45
Fibonacci 50% 24.86
Fibonacci 38.2% 22.27
Last Price 17.05
52-Week Low 13.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar